JP7317028B2 - 抗ガン剤として有用な置換キナゾリン誘導体と置換ピリドピリミジン誘導体 - Google Patents

抗ガン剤として有用な置換キナゾリン誘導体と置換ピリドピリミジン誘導体 Download PDF

Info

Publication number
JP7317028B2
JP7317028B2 JP2020542110A JP2020542110A JP7317028B2 JP 7317028 B2 JP7317028 B2 JP 7317028B2 JP 2020542110 A JP2020542110 A JP 2020542110A JP 2020542110 A JP2020542110 A JP 2020542110A JP 7317028 B2 JP7317028 B2 JP 7317028B2
Authority
JP
Japan
Prior art keywords
cancer
mmol
alkyl
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512131A5 (cg-RX-API-DMAC7.html
JP2021512131A (ja
Inventor
ブルーン,アレクセイ
チェン,ピン
チェン,ヘンミャオ
コリンズ,マイケル・レイモンド
リントン,マリア・アンジェリカ
マデルナ,アンドレアス
麻子 永田
パルマー,シンシア
プランケン,サイモン
スパングラー,ジリアン・エリス
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2021512131A publication Critical patent/JP2021512131A/ja
Publication of JP2021512131A5 publication Critical patent/JP2021512131A5/ja
Application granted granted Critical
Publication of JP7317028B2 publication Critical patent/JP7317028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020542110A 2018-02-01 2019-01-31 抗ガン剤として有用な置換キナゾリン誘導体と置換ピリドピリミジン誘導体 Active JP7317028B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862624829P 2018-02-01 2018-02-01
US62/624,829 2018-02-01
US201862685383P 2018-06-15 2018-06-15
US62/685,383 2018-06-15
US201962795062P 2019-01-22 2019-01-22
US62/795,062 2019-01-22
PCT/IB2019/050795 WO2019150305A1 (en) 2018-02-01 2019-01-31 Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents

Publications (3)

Publication Number Publication Date
JP2021512131A JP2021512131A (ja) 2021-05-13
JP2021512131A5 JP2021512131A5 (cg-RX-API-DMAC7.html) 2022-02-08
JP7317028B2 true JP7317028B2 (ja) 2023-07-28

Family

ID=65685851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542110A Active JP7317028B2 (ja) 2018-02-01 2019-01-31 抗ガン剤として有用な置換キナゾリン誘導体と置換ピリドピリミジン誘導体

Country Status (9)

Country Link
US (1) US10662204B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746435B1 (cg-RX-API-DMAC7.html)
JP (1) JP7317028B2 (cg-RX-API-DMAC7.html)
CA (1) CA3089936C (cg-RX-API-DMAC7.html)
ES (1) ES2926373T3 (cg-RX-API-DMAC7.html)
PY (1) PY1906086A (cg-RX-API-DMAC7.html)
TW (1) TW201942115A (cg-RX-API-DMAC7.html)
UY (1) UY38070A (cg-RX-API-DMAC7.html)
WO (1) WO2019150305A1 (cg-RX-API-DMAC7.html)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
WO2020097537A2 (en) 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
CN113382774A (zh) 2019-02-12 2021-09-10 诺华股份有限公司 包含tno155和krasg12c抑制剂的药物组合
ES3010507T3 (en) 2019-03-05 2025-04-03 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
CN112390788A (zh) * 2019-08-13 2021-02-23 苏州闻天医药科技有限公司 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
CN114222743A (zh) * 2019-08-16 2022-03-22 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物,其制法与医药上的用途
CN112390796B (zh) * 2019-08-19 2023-06-27 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114929706A (zh) * 2019-09-29 2022-08-19 百济神州有限公司 Kras g12c的抑制剂
CN112694475B (zh) * 2019-10-23 2025-09-23 苏州泽璟生物制药股份有限公司 环烷基类和杂环烷基类抑制剂及其制备方法和应用
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CN121471132A (zh) 2019-11-04 2026-02-06 锐新医药公司 Ras抑制剂
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN112851663B (zh) * 2019-11-12 2023-07-18 博瑞生物医药(苏州)股份有限公司 一种并杂环化合物及其用途
KR20260057216A (ko) * 2019-11-22 2026-04-27 세일 바이오메디슨스, 인크. Ahr 길항제로서의 피리도피리미디논 유도체
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
EP4015520B1 (en) * 2019-12-02 2025-02-19 280 Bio, Inc. Oxygen-containing heterocyclic compound, preparation method and application thereof
EP4069212A4 (en) * 2019-12-04 2024-03-06 Arcus Biosciences, Inc. INHIBITORS OF HIF-2ALPHA
CN113024544B (zh) * 2019-12-09 2024-07-02 武汉誉祥医药科技有限公司 一种含氰基并杂环化合物及其用途
JP2023512116A (ja) 2020-01-28 2023-03-23 プロテゴ バイオファーマ, インコーポレイテッド トランスサイレチンの安定化及びトランスサイレチンの誤った折り畳みの阻害のための化合物、組成物、及び方法
TW202140450A (zh) * 2020-02-24 2021-11-01 大陸商泰勵生物科技(上海)有限公司 用於癌症治療的kras抑制劑
AU2021228284A1 (en) * 2020-02-28 2022-09-29 Remix Therapeutics Inc. Compounds and methods for modulating splicing
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
MX2022012739A (es) * 2020-04-17 2022-11-07 Dong A St Co Ltd Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo.
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
WO2022028492A1 (en) 2020-08-05 2022-02-10 Beigene, Ltd. Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors
CA3191279A1 (en) 2020-08-28 2022-03-03 Yi Liu Heterocyclic compounds and uses thereof
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
WO2022066805A1 (en) 2020-09-23 2022-03-31 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITORS AND USE THEREOF
WO2022152313A1 (zh) * 2021-01-18 2022-07-21 成都百裕制药股份有限公司 嘧啶衍生物及其在医药上的应用
CN113072480B (zh) * 2021-04-13 2022-09-30 常州佳德医药科技有限公司 一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
BR112023024906A2 (pt) * 2021-05-28 2024-02-15 Redx Pharma Plc Compostos
CN115433179A (zh) * 2021-06-03 2022-12-06 正大天晴药业集团股份有限公司 苯并嘧啶类化合物及其医药用途
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途
WO2023009585A2 (en) 2021-07-28 2023-02-02 Protego Biopharma, Inc. Transthyretin stabilizing compounds
US20240374571A1 (en) 2021-09-01 2024-11-14 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
EP4389751A1 (en) 2021-09-03 2024-06-26 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
US12145901B1 (en) 2021-09-17 2024-11-19 Arcus Biosciences, Inc. Process for preparing tetralin compounds
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
US12030884B2 (en) 2021-10-01 2024-07-09 Incyte Corporation Pyrazoloquinoline KRAS inhibitors
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4476211A4 (en) * 2022-02-09 2026-02-25 Enliven Inc ACYLIC HETEROCYCLIC QUINAZOLINE DERIVATIVES USED AS ERBB2 INHIBITORS
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023199180A1 (en) 2022-04-11 2023-10-19 Novartis Ag Therapeutic uses of a krasg12c inhibitor
EP4511128A1 (en) 2022-04-20 2025-02-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
US20260015351A1 (en) * 2022-06-30 2026-01-15 Axonis Therapeutics, Inc. Methods and compounds for inhibiting mkk7 enzymes
JP2025528836A (ja) 2022-08-17 2025-09-02 ツリーライン バイオサイエンシズ インコーポレイテッド ピリドピリミジンKRas阻害剤
AU2023377064A1 (en) 2022-11-09 2025-05-22 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
KR20250109197A (ko) 2022-11-21 2025-07-16 트리라인 바이오사이언시스, 인크. 스피로환식 디하이드로피라노피리미딘 KRas 억제제
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
JPWO2024248123A1 (cg-RX-API-DMAC7.html) 2023-06-02 2024-12-05
EP4735451A1 (en) 2023-06-30 2026-05-06 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025213088A1 (en) * 2024-04-05 2025-10-09 Tenvie Therapeutics, Inc. Compounds, compositions, and methods
WO2025230971A1 (en) 2024-04-30 2025-11-06 Kumquat Biosciences Inc. Macrocyclic heterocycles as anticancer agents
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
TW202615038A (zh) 2024-08-07 2026-04-16 美商太斯萊特醫藥美國有限責任公司 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164675A1 (en) 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
JP2016532656A (ja) 2013-10-10 2016-10-20 アラクセス ファーマ エルエルシー Krasg12cの阻害剤
WO2017087528A1 (en) 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017201161A1 (en) 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
JP6869947B2 (ja) * 2015-07-22 2021-05-12 アラクセス ファーマ エルエルシー 置換キナゾリン化合物ならびにそのg12c変異kras、hrasおよび/またはnrasタンパク質の阻害剤としての使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016532656A (ja) 2013-10-10 2016-10-20 アラクセス ファーマ エルエルシー Krasg12cの阻害剤
WO2016164675A1 (en) 2015-04-10 2016-10-13 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017087528A1 (en) 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017201161A1 (en) 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Also Published As

Publication number Publication date
CA3089936C (en) 2023-02-28
US20190233440A1 (en) 2019-08-01
EP3746435A1 (en) 2020-12-09
JP2021512131A (ja) 2021-05-13
TW201942115A (zh) 2019-11-01
CA3089936A1 (en) 2019-08-08
EP3746435B1 (en) 2022-08-03
UY38070A (es) 2019-08-30
ES2926373T3 (es) 2022-10-25
WO2019150305A1 (en) 2019-08-08
US10662204B2 (en) 2020-05-26
PY1906086A (es) 2020-07-28

Similar Documents

Publication Publication Date Title
JP2021512131A (ja) 抗ガン剤として有用な置換キナゾリン誘導体と置換ピリドピリミジン誘導体
US10590115B2 (en) Tetrahydroquinazoline derivatives useful as anticancer agents
JP6609631B2 (ja) 縮合環ヘテロアリール化合物及びtrk抑制剤としての用途
WO2021037018A1 (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
CN107141293B (zh) 一种含氮杂环化合物、制备方法、中间体、组合物和应用
KR101985050B1 (ko) 피라진카르복사미드 화합물
CN107200749B (zh) Dna-pk抑制剂
CN111201223B (zh) SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
CN104125957B (zh) 取代的苄基吡唑
TWI786078B (zh) 金屬酶抑制劑化合物、抑制金屬酶活性之方法、使用金屬酶抑制劑化合物的方法及醫藥組成物
CN107148417A (zh) 苯并氮杂*磺酰胺化合物
US20220388964A1 (en) (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
MXPA06001762A (es) Derivados de piperazina.
WO2004020434A1 (ja) 含窒素芳香環誘導体
JP2017522346A (ja) ブロモドメインに対して活性な化合物
EP2935261A1 (de) Bet-proteininhibitorische dihydrochinoxalinone
CN104870448A (zh) 三唑并吡嗪
JP2019507766A (ja) 線維症の治療のための新規化合物及びその医薬組成物
EP3247705B1 (en) Quinazoline and quinoline compounds and uses thereof as nampt inhibitors
KR20170095243A (ko) Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체
CN101218227A (zh) 作为因子Xa的抑制剂的杂环磺酰胺衍生物
ZA200505957B (en) Triazole compounds useful in therapy
WO2022188792A1 (zh) 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
JPWO2001083460A1 (ja) 環状化合物
HK1144423A (en) Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230718

R150 Certificate of patent or registration of utility model

Ref document number: 7317028

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150